Infection and Vaccines

Addressing infectious diseases

AstraZeneca is committed to developing and implementing scientific advancement in infection and vaccines.

We work to protect patients against the burden of influenza and bacterial infections, particularly those resistant to current antibiotics.

In Europe, antimicrobial resistance results in 25,000 deaths from hospital-acquired infections, while there are 3-5 million severe cases of influenza each year worldwide.

Demand for health interventions to address these burdens of disease remains high and, through working with the wider infection community, AstraZeneca aims to translate science into solutions to address global challenges faced in these disease areas.

Our focus on infectious diseases

Infectious diseases are the second-leading cause of death worldwide, after heart disease, and are responsible for more deaths annually than cancer.

  • Antimicrobial resistance (AMR)

    AMR is a major public health threat. As bacteria develop resistance to current antibiotics, deadly infections could, again, become uncontrollable.


  • Seasonal influenza

    Seasonal influenza is a serious public health problem that causes severe illness and death in high-risk populations.


25,000

In Europe alone, AMR causes 25,000 deaths every year; two thirds of these are due to Gram-negative bacteria.

1.5 billion

AMR will result in 1.5 billion EUR extra healthcare costs and productivity losses across Europe, based on 2007 estimates.

1 billion

There are an estimated 1 billion cases of influenza each year worldwide.

300,000-500,000

Each year there are around 300,000-500,000 deaths due to influenza worldwide.

What we've been working on

Our pipeline

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.

Phase 3/Reg.* refers to assets that are in Phase 3 or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.

Other (as at 10 November)

Phase 1

Phase 1

  • AZD8108 suicidal ideation
  • MEDI0700 systemic lupus erythematosus
  • MEDI1814 Alzheimer’s disease
  • MEDI4920 primary Sjögren’s syndrome
  • MEDI7352 osteoarthritis pain
  • MEDI7734 myositis
  • anifrolumab systemic lupus erythematosus (subcutaneous)

Phase 2

Phase 2

  • ATM AVI targeted serious bacterial infections
  • AZD3241 multiple system atrophy
  • CXL MRSA
  • MEDI2070 Crohn’s disease
  • MEDI3902 prevention of nosocomial pseudomonas pneumonia
  • MEDI4893 hospital-acquired pneumonia/serious S. aureus infection
  • MEDI5872 primary Sjögren’s syndrome
  • MEDI7510 prevention of RSV disease in older adults
  • MEDI8852 influenza A treatment
  • MEDI8897 passive RSV prophylaxis
  • anifrolumab lupus nephritis
  • inebilizumab neuromyelitis optica
  • mavrilimumab rheumatoid arthritis
  • verinurad chronic treatment of hyperuricemia in patients with gout

Phase 3

Phase 3

  • AZD3293 AMARANTH DAYBREAK-ALZ Early Alzheimer's disease
  • Zavicefta (CAZ AVI) serious infections, complicated intraabdominal infection, complicated urinary tract infection
  • Zavicefta (CAZ AVI) hospital-acquired pneumonia/ ventilator-associated pneumonia
  • Zinforo pneumonia/skin infections
  • anifrolumab TULIP systemic lupus erythematosus

LCM Projects

LCM Projects

  • Nexium stress ulcer prophylaxis
  • Nexium paediatrics
  • linaclotide irritable bowel syndrome with constipation (IBS-C)

Our medicines

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.

  • Synagis palivizumab
  • Fluenz Tetra/FluMist Quadrivalent influenza vaccine live, intra-nasal
  • Merrem/Meronem meropenem
  • Zinforo ceftaroline fosamil

Resources